dc.contributor.author | Azeem, Waqas | |
dc.contributor.author | Bakke, Ragnhild Maukon | |
dc.contributor.author | Gabriel, Benjamin | |
dc.contributor.author | Appel, Silke | |
dc.contributor.author | Øyan, Anne Margrete | |
dc.contributor.author | Kalland, Karl-Henning | |
dc.date.accessioned | 2022-04-12T12:06:34Z | |
dc.date.available | 2022-04-12T12:06:34Z | |
dc.date.created | 2021-08-19T10:27:27Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 2227-9059 | |
dc.identifier.uri | https://hdl.handle.net/11250/2991081 | |
dc.description.abstract | Modulation of β-catenin signaling has attractive therapeutic potential in cancer immunotherapy. Several studies have found that β-catenin can mediate immune evasion in cancer and promote anti-inflammatory features of antigen-presenting dendritic cells. Many small molecular compounds that inhibit Wnt/β-catenin signaling are currently in clinical development, but none have entered routine clinical use. New inhibitors of β-catenin signaling are consequently desirable. Here, we have tested, in monocyte-derived dendritic cells, the effects of two small molecular compounds, axitinib and nitazoxanide, that previously have been discovered to inhibit β-catenin signaling in colon cancer cells. Immature and lipopolysaccharide-matured dendritic cells prepared from healthy blood donor buffy coats were stimulated with 6-bromoindirubin-3′-oxime (6-BIO) to boost basal β-catenin activity, and the effects of axitinib and nitazoxanide were compared with the commercial β-catenin inhibitor ICG-001. Assays, including genome-wide RNA-sequencing, indicated that neither axitinib nor nitazoxanide demonstrated considerable β-catenin inhibition. Both compounds were found to be less toxic to monocyte-derived dendritic cells than either 6-BIO or ICG-001. Axitinib stimulated several aspects of dendritic cell function, such as IL12-p70 secretion, and counteracted IL-10 secretion, according to the present study. However, neither axitinib nor nitazoxanide were found to be efficient β-catenin inhibitors in monocyte-derived dendritic cells. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Evaluation of β-catenin inhibition of axitinib and nitazoxanide in human monocyte-derived dendritic cells | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.source.articlenumber | 949 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/biomedicines9080949 | |
dc.identifier.cristin | 1927176 | |
dc.source.journal | Biomedicines | en_US |
dc.identifier.citation | Biomedicines. 2021, 9 (8), 949. | en_US |
dc.source.volume | 9 | en_US |
dc.source.issue | 8 | en_US |